MTOR and bladder transitional cell carcinoma: Matsushima et al showed a decreasing trend in bladder weight and levels of pAKT, pS6, and p4EBP1 in the NVP-BEZ235-treated group compared with the control group, suggesting that NVP-BEZ235 exerts a significant antitumor effect by inhibiting the PI3K/AKT/mTOR pathway.[57] The combination of NVP-BEZ235 with cisplatin demonstrates significant synergistic antitumor effects in cisplatin-resistant BLCA cells.